O-RAN-ALLIANCE-E.V.
15.3.2023 23:28:35 CET | Business Wire | Press release
Memorandum of Understanding between O-RAN ALLIANCE and OpenAirInterface Software Alliance (OAI)
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230315005917/en/
In recently signed Memorandum of Understanding, OAI and O-RAN ALLIANCE agreed to co-operate on open Radio Access Network issues, open source software development, and 5G as well as next generation platforms for demonstrating O-RAN technology. Both organizations will encourage sharing of information in areas of mutual interest and may hold joint meetings and workshops.
”I am very pleased to see the excellent cooperation between O-RAN and OAI,” said Alex Jinsung Choi, Chair of the Board of O-RAN ALLIANCE and SVP Group Technology, Deutsche Telekom. “The MoU will strengthen our cooperation in development of open source software for the RAN. It will allow a more focused cooperation between both organizations and will enhance our software development.”
“We are very excited at the signing of this MoU,” said Raymond Knopp, President of the OpenAirInterface Software Alliance. “This has been a long standing goal for the OpenAirInterface Software Alliance. Firstly, the OAI software follows the O-RAN architecture and paves the way for showcasing the next generation cellular wireless technologies. Secondly, the two organizations are very complementary in their value propositions. We look forward to capitalizing on this collaboration in the future.”
Two New Open Testing and Integration Centres (OTIC) Approved in Asia & Pacific
O-RAN ALLIANCE announces that Asia & Pacific OTIC by ritt7layers and Asia & Pacific OTIC in Singapore have joined the community of Open Testing and Integration Centres. With this addition there are now 11 approved OTICs across Europe, the Americas, and Asia.
OTICs are vendor-independent, open, and qualified labs approved by the O-RAN ALLIANCE that issue awards in the O-RAN Certification and Badging Program.
For more information about OTICs and O-RAN ALLIANCE’s testing and integration work please visit our website.
O-RAN Release 3 Implements Features with 58 New or Updated Technical Documents
O-RAN Release 003 includes enhancements to RAN Slicing and SMO features. It also introduces new features:
- Security requirements and countermeasures for RAN Intelligent Controller (RIC) interfaces and apps, O-Cloud and O2 interface
- Security technical reports with threat and risk analysis outputs for application lifecycle management, log management, service management and orchestration, shared O-RU
- RIC-enabled massive MIMO optimization for non-Grid of Beams (GoB) beamforming method
- RAN Analytics Information Exposure (RAIE) use cases and RIC architecture enhancements for extending RAN-aware optimization capabilities to external services and applications
O-RAN Release 003 also includes 10 new specification titles:
- Network Energy Savings Use Cases Technical Report
- Decoupled SMO Architecture Technical Report
- Application Protocols for R1 Services
- O1 Interface Specification for Near-RT RIC
- Near-RT RIC APIs specification
- Requirements and Reference Design Specification for Enterprise Microcell
- Study on Security for Application Lifecycle Management
- Study on Security Log Management
- Study on Security for Service Management and Orchestration (SMO)
- Study on Security for Shared O-RU
For more details about newly released O-RAN specifications please read our web announcement. All O-RAN specifications are available for download at our website.
O-RAN Global PlugFest Spring 2023 Set to Start at Labs Across Asia, Europe, and North America
The first of the two O-RAN Global PlugFests planned for 2023 will be held in:
- South Korea hosted by KT
- Taiwan hosted by Auray Technology
- Europe hosted by Deutsche Telekom, EANTC, EURECOM, Orange, Telefónica and Vodafone
- USA hosted by University of New Hampshire InterOperability Laboratory
More than 55 companies have indicated their plan to participate.
Planned activities include interoperability and E2E testing, validation and demonstration of Radio Intelligent Controller (RIC) use cases, as well as X-haul transport, O-Cloud, QoS, and security testing.
F2F Meetings Boost Progress of O-RAN Technical Groups
With the easing of pandemic restrictions, O-RAN ALLIANCE resumed face-to-face meetings of its technical groups, greatly accelerating progress in specifications development. Latest F2F meetings took place in February 2023 in Prague with more than 430 delegates from 115 companies and institutions around the world. O-RAN plans to hold two more F2F meetings in 2023, one in June and one in October.
About O-RAN ALLIANCE
The O-RAN ALLIANCE is a world-wide community of more than 300 mobile operators, vendors, and research & academic institutions operating in the Radio Access Network (RAN) industry. As the RAN is an essential part of any mobile network, the O-RAN ALLIANCE’s mission is to re-shape the industry towards more intelligent, open, virtualized and fully interoperable mobile networks. The new O-RAN specifications enable a more competitive and vibrant RAN supplier ecosystem with faster innovation to improve user experience. O-RAN based mobile networks at the same time improve the efficiency of RAN deployments as well as operations by mobile operators. To achieve this, the O-RAN ALLIANCE publishes new RAN specifications, releases open software for the RAN, and supports its members in integration and testing of their implementations.
For more information, please visit www.o-ran.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230315005917/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom